No profile data available.
Beryl Drugs Limited (BERLDRG.BO) is a healthcare company in the drug manufacturing contractors industry, based in Indore, India.
It reported revenue of 209.44 million INR for fiscal year 2025, down 20.8% from fiscal year 2024, and net income of 5.79 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 37.77 million INR, down 28.9% from a year before. Its market capitalization was 133.44 million INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
Beryl Drugs Limited engages in the manufacture and marketing of pharmaceutical products in India. V. fluids, small volume injectables in liquid and dry powder forms, and eye and ear drops, as well as veterinary products. The company also provides research and development, and contract manufacturing services. It exports its products.
Beryl Drugs reported 209.44 million INR in revenue for fiscal year 2025, down 20.8% from 264.47 million INR in fiscal year 2024. In Q3 2026 revenue was 37.77 million INR.
133.44 million INR as of October 9, 2026.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include Samsrita Labs Limited (SAMSRITA.BO), Ishita Drugs and Industries Limited (ISHITADR.BO), Zenith Healthcare Limited (ZENITHHE.BO), Ortin Global Limited (ORTINGLOBE.NS).